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A PROSPECTIVE STUDY OF NEONATAL WITHDRAWAL IN INFANTS EXPOSED TO 
COCAINE AND METHADONE. Barbara A. McGee and Linda C. Mayes. Child Study Center, 
Yale University School of Medicine, New Haven, CT. 
The purpose of the present study was to prospectively examine the following hypothesis: Cocaine 
use among pregnant women maintained on methadone increases the duration and the severity of 
the neonatal abstinence syndrome (NAS) among their infants. A group of 23 infants born to 
mothers participating in a methadone maintenance program were followed for severity of NAS 
after poly-drug exposure in utero. Severity of withdrawal was indexed by infant length of stay in 
the hospital, duration of treatment with medication, first and maximum symptom scores, and the 
dosages of withdrawal medications used. During pregnancy, information was gathered on 
maternal daily methadone dose, urine toxicology, pregnancy complications, and medication use. 
Fourteen (61%) of the mothers in the sample had positive urine screens for cocaine, and five 
(22%) took benzodiazepines regularly during pregnancy. Infants exposed to both cocaine and 
methadone trended toward a shorter duration of therapy, however, the differences were not found 
to be statistically significant (F = 1.54 , p = .23). There was a positive correlation between 
maternal methadone dose and the number of days infants spent on the highest doses of 
withdrawal medication (r = .53, p < .01). In addition, benzodiazepine exposure significantly 
contributed to longer infant hospital stays (F = 8.3, p < .01), and duration of medication treatment 
(F = 10.37, p < .01). These findings suggest that the effect of cocaine on withdrawal from 
methadone in infants is small, having either no contributory effect or only a mild degree of 
shortening of the duration of withdrawal symptoms. 
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Substance abuse in pregnancy 
More than 100,000 babies born in the United States annually are believed to have 
been exposed to cocaine or other drugs during the critical period of fetal brain 
development.1 The National Institute on Drug Abuse reports 70 to 90% of Americans 
between the ages of 15 to 40 years have used mood-altering chemicals, approximately half 
of whom are women with reproductive potential.2 Among women in this group, 
approximately 60% drink alcohol, 32% smoke nicotine cigarettes, and 11% use marijuana. 
Some reports suggest a leveling off of overall cocaine use in this country over the last five 
years.3 However, young women continue to be the fastest growing group of cocaine users, 
with some cities reporting a 12 to 15% increase in cocaine use among women since 1991. 
In a population of women presenting for prenatal care, screening a single urine sample for 
alcohol, cannabinoids, cocaine, and opiates reveals positive urine toxicology results in 3 to 
50% of cases, depending on the methods and populations studied.4'6 
A 1988 study,2 conducted by the National Association of Perinatal Addiction 
Research and Education, and involving approximately 155,000 pregnancies annually from 
36 hospitals around the country, found that 11% of the mothers used at least one of the 
following: heroin, methadone, marijuana, PCP, amphetamines, and most commonly 
cocaine. A later study of infants born to substance abusing mothers in New York City 
revealed the changing patterns of drug exposure through the 1980's.7 Initially, heroin and 
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methadone use during pregnancy predominated. As crack became more readily available, 
the trend began to shift toward increasing cocaine use in pregnancy, with frequency of 
cocaine use being reported on birth certificates 2.3 times more frequently than heroin and 
methadone combined. Frequently, more than one drug is being abused during pregnancy. 
Among women maintained on methadone for opiate addiction, concomitant, regular use of 
cocaine or crack has been reported in 20 to 60%.8,9 
The increase in cocaine use among women of reproductive age has caused concern 
about the potential maternal and fetal effects of illicit drug abuse during pregnancy. 
Pregnancy in women who use illegal drugs or alcohol is, by definition, a high risk. In 
untreated women who use cocaine during pregnancy, serious complications have been 
reported, such as maternal deaths, myocardial infarction, cerebrovascular accidents, and 
abruptio placentae.10'18 A correlation exists between substance abuse in pregnancy and a 
higher exposure to sexually transmitted diseases, systemic infections including HIV, poor 
nutrition, decreased use of health services, and indiscriminate sexual activity.1213,19 -21 
These factors, as well as the chaotic lifestyle that accompanies substance abuse,22 creates 
a high-risk environment for fetal development, warranting concern about the outcome of 
infants exposed to drugs in utero. 
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Neonatal abstinence syndrome 
One clear outcome of substance abuse in pregnancy is exhibited by the neonatal 
withdrawal syndrome experienced by infants born to opiate-addicted mothers. Newborns 
who have been exposed prenatally to heroin or methadone are born passively addicted to 
the drug and exhibit withdrawal symptoms in the first days to weeks after delivery.23"25 
Heroin and methadone are easily transferred across the placenta, and have been found to 
accumulate in fetal tissues and fluids when exposure occurs during gestation.26 27 Neonatal 
Abstinence Syndrome (NAS) results when the placental transfer of opiates to the infant is 
disrupted by delivery. The majority of infants bom to opiate-addicted women experience 
NAS,28 which is characterized by signs and symptoms of central nervous system 
hyperirritability, gastrointestinal dysfunction, respiratory distress, poor sucking reflex, 
tremors, hypertonicity, and high pitched crying (Figure 1). The majority of symptoms appear 
within 72 hours of delivery.29 Several types of clinical courses have been described in the 
literature on NAS.29 Withdrawal has been noted to be mild and brief, be delayed in onset, 
have a step-wise increase in severity, or have a biphasic course. More severe withdrawal 
tends to occur in infants whose mothers have taken large amounts of drugs for a long 
time.30 31 In general, the closer to delivery a mother takes heroin, the greater the delay in 
onset of withdrawal and the more severe the symptoms in her baby. Duration of symptoms 
can extend from six days to twelve weeks depending on the extent of drug exposure, as 
well as concomitant medical problems of the infant. During the later weeks of withdrawal, 
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infants may have hyperphagia, increased sucking, sweating, irregular sleep patterns, loose 
stools, and poor tolerance to holding or to abrupt changes of position and space.29 
The severity of withdrawal in an infant exposed to opiates in utero is generally 
monitored by following specific symptoms with a standardized scoring system. An early 
scoring system was proposed by Lipsitz32 to quantitate the clinical symptoms of abstinence. 
The degree of tremor, irritability, and gastrointestinal symptoms were scored from zero to 
three, based on observer judgement. The presence or absence of tachypnea, sneezing, 
yawning, vomiting, and fever were noted and scored as either zero or one. A cumulative 
withdrawal score was then calculated and the assessment could be repeated at a standard 
frequency during the infant hospital stay. In this way, infants were compared to each other 
and the progression of withdrawal severity was monitored in individual infants. A more 
detailed system of scoring was developed and standardized by Finnegan,33 which serves as 
the basis for most withdrawal measuring systems currently in use at pediatric hospitals in 
this country (Figure 2). The Finnegan scale measures 21 signs of withdrawal and allows 
scores to be obtained at regular intervals during a twenty-four hour period. The scores 
obtained serve as a means for communication regarding withdrawal severity within research 
studies, as well as a clinical measure utilized when making treatment decisions. 
When abstinence scores for an infant exposed to opiates reach a particular 
threshold, pharmacotherapy may be used to alleviate withdrawal symptoms. Treatment is 
usually initiated within the first days of life. Symptoms are brought under control and the 
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infant is gradually withdrawn from the medication. Medication for withdrawal has typically 
consisted of either opiate substitutes,31 34 35 or nonspecific depressants such as 
phenobarbital,36 diazepam,31 and chlorpromazine.34,36,37 Paregoric, a tincture of opium, is 
generally considered the treatment of choice for NAS in this country.38 Phenobarbital is 
often added or used as a second line drug for symptom control. Although morbidity 
associated with NAS is decreased with treatment, therapeutic management may require a 
prolonged hospital stay. 
Methadone maintenance during pregnancy 
It has been reported that entry into a methadone maintenance program serves to 
encourage better participation in prenatal care and provide a more stable environment for 
pregnant opiate addicts.39,40 Methadone is a long-acting synthetic opioid that can be taken 
by mouth, thereby reducing the risk of infection acquired by the sharing of contaminated 
needles or syringes as in heroin use. Methadone blocks the euphoria produced by heroin 
and blunts the appetite for repeated administration of opiates. A free and regular supply of 
methadone from an established clinic also decreases the likelihood that patients will engage 
in prostitution or criminal activities which are detrimental to their physical and mental well¬ 
being. Also, it has been argued that with steady methadone maintenance the fetus would 
not suffer from fluctuating levels of opiates and therefore the incidence of intrauterine 
withdrawal would be less.40 It has been shown that methadone maintenance, in conjunction 
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with adequate prenatal care, significantly reduces the incidence of medical and obstetrical 
complications and prematurity.41 Studies have also consistently found differential effects of 
heroin and methadone on birth weight, with higher birth weight infants born to women 
maintained on methadone.24 42 
It has been suggested that methadone produces more severe withdrawal 
manifestations than heroin.34 35 However, measurement of heroin intake is rarely possible, 
and most studies have been laden with the dilemma of concurrent poly-drug use. The 
severity of the neonatal abstinence syndrome may largely be determined by total 
intrauterine drug exposure.43 44 Many studies have debated the relationship of total 
maternal methadone intake, and by extension total fetal exposure, to the severity of 
subsequent neonatal withdrawal symptoms.38 45 46 Doberczak et al,46 in 1993, studied a 
group of 21 methadone-dependent women and their infants to define the relationship 
between neonatal opiate withdrawal and maternal methadone dose. They found that higher 
initial plasma methadone levels were associated with more rapid declines of drug levels in 
methadone-exposed neonates. The more rapid rate of decrease in serum methadone 
levels after birth correlated significantly with acuity of central nervous system withdrawal 
signs observed in their sample of infants. These results are consistent with animal studies 
which have shown that methadone accumulates in the non-human primate brain during 
gestation, resulting in significantly higher brain levels compared with fetal plasma levels.47 48 
In addition, intrauterine exposure of the fetal brain to opiates promotes regional 
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development of specific opiate receptors and suppresses neurotransmitter formation and 
function.26 49 Thus, a more rapid decline in methadone levels in the first hours after delivery 
would produce a rapid shift of drug out of brain tissue, leading to increased availability of 
specific opiate receptors as well as rapid replenishment of neurotransmitters. In the 
presence of increased receptor sites, this replenishment of neurotransmitters would 
produce neuronal excitability, clinically manifested as central nervous system signs of 
withdrawal such as irritability, tremors, hyperreflexia, and possibly seizures.46 
With the potential for a more severe withdrawal course in infants exposed to 
methadone, the suggestion has been made that lowering dosages of methadone late in 
pregnancy may ameliorate neonatal opiate withdrawal, and thereby benefit the mother and 
infant.46 50 However, methadone regimens are generally individualized to determine the 
dose that will prevent the development of withdrawal symptoms in a pregnant woman. If 
the reduction of methadone dosage is attempted, there is always the fear of fetal instability 
from withdrawal,51 or the possibility of fetal death.52 In addition, dosage reduction carries 
the risk of maternal discomfort and self-medication with street drugs, thus increasing 
neonatal morbidity and decreasing the overall value of methadone maintenance to the 
health of the woman. 
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Outcome after fetal opiate exposure 
Maternal opiate addiction is associated with increased perinatal morbidity and 
mortality.53 Problems associated with heroin use during pregnancy include first-trimester 
spontaneous abortion, premature delivery, meconium staining, and maternal and neonatal 
infections.54 In general, studies that have compared birth outcomes of opiate exposed 
infants and non-drug exposed infants have consistently found opiate exposed infants to 
have lower birth weights than comparison infants.4142 55 56 Although the birth weights of 
methadone exposed infants are higher than those of heroin addicts, they are still less than 
nonaddicted controls.57 In addition, numerous studies have now replicated the finding that 
prenatal opiate exposure reduces head circumference.4142 58 Similar findings in animal 
models that control for exposure to other drugs such as alcohol or tobacco, and for poor 
maternal health support the finding of an effect of opiates on fetal growth.59 Prenatal 
exposure to opiates may contribute significantly to an increased incidence of sudden infant 
death syndrome (SIDS)7. In some studies, the incidence of SIDS is eight times that 
reported for non-opiate-exposed infants.60'62 
Past the neonatal period, a number of studies have documented small, and not 
usually statistically significant, delays in the acquisition of developmental skills as measured 
by the Bayley Scales of Infant Development.56 58 62 63 However, much more consistent 
across studies have been the findings of persistent problems in poor motor coordination, 
high activity level, and poor attention among opiate-exposed infants in the first year of 
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life.64,65 Similarly, opiate-exposed school-age children show higher activity levels, are often 
impulsive with poor self-control, show poor motor coordination, and have more difficulty with 
tasks requiring focused attention.66,67 Maternal poly-drug use has been a major 
confounding factor in studies investigating the effects of prenatal exposure to illicit drugs. 
As well, the effect of the care-taking environment for children in substance-abusing families 
is undoubtedly a significant factor in developmental outcome, and has not consistently been 
controlled for in scientific studies. 
Cocaine use in pregnancy 
Cocaine is one of the most frequently used illicit drugs, with national trends 
indicating that cocaine, and in particular crack, continues to dominate the drug scene.3 
Although overall use of cocaine appears to have leveled off in most cities in the United 
States, some indicators point to an increase in the number of female cocaine users.3 Crack 
remains the most popular form of cocaine, presumably due to the ready availability and low 
cost of the drug. In Philadelphia, a large rock, or boulder, sells for about five dollars. In 
Seattle, little bits of crack called kibbles sell for one dollar.3 With crack so easily available, 
the incidence of cocaine use in pregnancy has been reported at 10 to 19%.4,68-70 
Cocaine is a powerful stimulant drug that in its freebased form, crack, can be 
smoked to induce short periods of intense euphoric feelings, during which energy and self¬ 
esteem are enhanced and anxiety are decreased.71 However, within hours of use, 
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cocaine's rebound effects result in anxiety, exhaustion, and depressive feelings. The 
dependent person takes cocaine repeatedly to avoid the crash rebound effects. Chronic 
use can result in psychologic and physical symptoms, including paranoid and mood 
disorders, weight loss, and decline in judgment.72 In adults, the acute and chronic effects of 
cocaine are demonstrated through significant alterations of central nervous system 
function.11,73 
Due to cocaine’s low molecular weight and its water and lipid solubility, it readily 
crosses the placenta and the fetal blood brain barrier.74 Plasma cholinesterase, which 
inactivates cocaine, is relatively deficient in the mother and fetus, possible resulting in a 
greater time of exposure to the active drug. One adverse effect of cocaine on the fetus is 
uterine vessel vasoconstriction with reduced uterine blood flow and oxygen transfer.75 
Experiments in animals have also suggested a teratogenic effect,76 and permanent 
degeneration of nerve terminals in adult animals.77,78 Thus, cocaine may have direct 
neurotoxicity or indirect effects via vasoconstriction on the developing nervous system. 
Cocaine and central nervous system development 
The primary central nervous system (CNS) action of cocaine occurs through the 
monoaminergic neurotransmitter systems including dopamine, norepinephrine, and 
serotonin (5-HT). Cocaine blocks the reuptake of dopamine, norepinephrine, and 5-HT by 
the presynaptic neuron, a process that is primarily responsible for inactivation of 

neurotransmitters.79 Blocking reuptake leaves more monoamine neurotransmitters 
available within the synaptic space and results in enhanced activity of these agents in the 
CNS. The various dopamine-rich areas of the brain are involved in a number of basic 
neuropsychological functions including arousal and attentional modulation, the regulation of 
anxiety and other emotional states, and the reinforcing properties basic to stimulant 
addiction in adults. In fetal brain development, monoaminergic neurotransmitters are critical 
for the definition of brain structure and neuronal formation through their effects on cell 
proliferation, neural outgrowth, and synaptogenesis.80,81 Alterations in developing 
monoaminergic systems may lead to mistimed neurogenesis, and resultant alterations in 
synaptic connections.82 In addition, prenatally cocaine-exposed infants might be expected 
to be compromised specifically in areas such as reactivity, capacity to modulate levels of 
arousal in response to stimulation, and attentional regulation.83 
Perinatal complications associated with cocaine use 
Numerous reports have described significant obstetric and neonatal complications 
associated with maternal cocaine use during pregnancy. Among the most compelling 
findings are consistent descriptions of increased rates of spontaneous abortions, abruptio 
placentae, and meconium-stained amniotic fluid.17,28,68,84 Intrauterine growth retardation 
has been found in all studies of reasonable size in which cocaine-exposed neonates were 
compared with non-drug-exposed newborns.18,28,68,85,86 
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Increased rates of prematurity and lowered gestational age in cocaine-exposed 
pregnancies have been found,17 86 88 suggesting that prematurity or its complications may 
be indirect mechanisms by which cocaine’s neurodevelopmental effects are expressed. 
Alternatively, premature birth may be a marker for mothers with greater dependency on 
drugs, a heavier use of drugs, or significant socioeconomic disadvantages.72 Marijuana 
use, alcohol use, and cigarette use have also been shown to be significant independent or 
interactive contributors to reduced fetal health in samples of poor, urban, minority pregnant 
women.18,84 Some available studies have had methodologic problems that prevent clear 
attribution of the poor medical outcomes of cocaine-exposed pregnancies to cocaine use 
alone. These problems include poorly defined or highly selective samples, misidentification 
of subjects, lack of appropriate comparison groups, and retrospective sampling.89 
Infant outcome after prenatal cocaine exposure 
Exposure to cocaine and other drugs places infants at risk for developmental 
dysfunctions. For example, infant neurological examinations soon after birth have 
documented increased tremors, irritability, and hypertonicity in infants exposed to cocaine.31 
90 91 The Brazelton Neonatal Behavioral Assessment Scale (NBAS) has been the most 
consistently used assessment of newborn neurobehavioral characteristics,92 '94 and it is 
frequently the outcome measure of choice in studies of the neurobehavioral effects of 
prenatal drug or potential teratogen exposure.17,65 95 In three studies to date, reporting on 
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cocaine exposure without concomitant opiate use, and with or without concomitant alcohol 
use, findings have been inconsistent.1 84,95 Chasnoff and colleagues1 found impairments of 
orientation, motor, and state regulatory behaviors on the NBAS. In contrast, Coles et al84 
reported that NBAS scores for all newborns fell within a clinically normal range regardless of 
cocaine or alcohol exposure. Although significant differences emerged between groups for 
autonomic regulation and for abnormal reflexes, the less optimal performance was not 
consistently more frequent among the cocaine-exposed group only, and no clear patterns of 
effect emerged. Finally, Eisen and colleagues,95 studying neonates who were urine screen 
positive only for cocaine at birth and whose mothers denied opiate use, found significant 
differences in habituation performance as assessed by the NBAS. Habituation is involved 
with attention and information processing and perhaps learning in infants.96 Depressed 
habituation performance on the NBAS in infants exposed to cocaine would suggest a link 
between the effects of cocaine on the developing brain and neurobehavioral outcome. 
In early reports regarding the long-term developmental outcome of infants exposed 
to cocaine as well as combinations of heroin, methadone, and marijuana, cocaine exposure 
was predictively linked to moderate to severe developmental delays across diverse 
developmental domains.97 However, subsequent studies have reported mild to no 
impairments in overall developmental functioning in cocaine-exposed children compared to 
non-exposed groups.98 99 The findings from a 3-year outcome study by Azuma and 
Chasnoff100 indicated that prenatal substance exposure had a significant effect on cognitive 
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abilities as measured by the Stanford-Binet scale. It was acknowledged, however, that the 
nature of the effect on intellectual outcome is complex, due to the influences of home 
environment, child behavior, and head circumference which confound studies with this 
group of children. Therefore, other causal models for attributing poor Stanford-Binet scores 
to a drug exposed population of children could not be ruled out. Therefore, such factors as 
socioeconomic status, behavioral characteristics, and quality of the home environment 
continue to complicate the ability to draw conclusions from studies of drug exposure in 
children. 
Interactive effect of cocaine and opiates 
Infants with combined exposure to narcotics and cocaine have been shown to have 
a worse perinatal outcome when compared to other drug exposures in pregnancy.88 Among 
women maintained on methadone for opiate addiction, concomitant, regular cocaine or 
crack use has been reported in 20 to 60%.8,9 Combinations of opiate and cocaine use 
during pregnancy raise concerns about a potentially interactive effect on the withdrawal 
syndrome, and exacerbation of adverse perinatal outcomes. In a phenomenon called the 
“kindling effect," repeated doses of cocaine result in progressively increasing central 
nervous system sensitivity, thereby increasing reactivity to the central effects of other 
drugs.101 102 Pinel and Van Ott reported that repeated cocaine administration in animals 
leads to more severe withdrawal from a second drug such as heroin and amphetamines.103 
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There are conflicting reports published regarding the interactive effect between 
cocaine and opiates. In adult opiate addicts applying for methadone maintenance, it has 
been reported that cocaine significantly lowered levels of naloxone-precipitated 
withdrawal.104 However, adult patients in another study reported that cocaine use 
precipitated symptoms similar to opiate withdrawal.105 For human infants potentially 
interactive effects between cocaine and opiates on neonatal withdrawal have been reported 
for infants exposed to heroin and cocaine prenatally. Fulroth and colleagues studied the 
withdrawal course of 86 infants after maternal heroin use.106 Seventeen infants were 
exposed to both heroin and cocaine, and 14 to heroin alone. Using the Finnegan scoring 
system, infants were treated for withdrawal when scores were greater than 12 over an eight 
hour period in the first five days of life. In their population of patients a significant difference 
was found between the withdrawal course of heroin-only infants and those exposed to both 
opiates and cocaine. They found that 21% of the infants exposed only to heroin required 
treatment for withdrawal, compared with 47% of the infants exposed to both heroin and 
cocaine. The conclusion drawn from this data was that cocaine had a synergistic effect on 
the withdrawal syndrome seen after in utero heroin exposure. 
In contrast, in the retrospective study by Mayes and Carroll,107 suggested that the 
effect of cocaine, if any, on neonatal opiate withdrawal was most notable in the initial phase 
of withdrawal. In their study, 68 women and infant pairs were analyzed for measures of 
withdrawal severity. In that cohort, cocaine exposure resulted in significantly higher first 

16 
withdrawal scores, but there were no significant differences in the amount of time on 
withdrawal medication or the maximum doses of paregoric required for withdrawal 
treatment. 
Another study to look at the specific question of cocaine effects on opiate 
withdrawal was performed by Ryan et al.108 In that study, 50 methadone-exposed infants 
were compared with 50 methadone and cocaine-exposed infants, using parameters of 
neonatal morbidity and mortality, as well as abstinence scoring immediately after birth to 
determine outcome. The most significant findings included lower birth weight, length, and 
head circumferences for cocaine-exposed infants when compared with a group of infants 
not exposed to cocaine or methadone. In addition, their data suggested a higher rate of 
fetal loss and infant mortality after cocaine exposure in pregnancy. To determine the effect 
of cocaine exposure on neonatal abstinence severity in that population, Ryan et al 
compared individual symptom frequency, as scored on the Finnegan scale. It was noted 
that episodes of abstinence symptoms occurred less frequently in infants exposed to a 
combination of cocaine and methadone in 19 of the 21 symptom categories. This trend was 
not found to be statistically significant, thus the authors concluded that cocaine exposure 
had no effect on the severity of withdrawal in opiate-exposed infants. 
Finally, Doberczak and colleagues examined the effects of gestational age on the 
neonatal abstinence syndrome, with and without concomitant cocaine exposure.109 In this 
cohort of methadone-maintained mothers, severity of abstinence symptoms correlated with 
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maternal methadone dosage, but was not influenced by maternal multiple drug use. 
Therefore, with the results of current research available, the question of how cocaine affects 
the severity of neonatal withdrawal from opiates remains inadequately answered. It could 
be hypothesized, based on a review of the literature, that cocaine exposure would 
exacerbate the central nervous system irritability that is a central aspect of the neonatal 
abstinence syndrome. Theoretically, the direct stimulant effects of cocaine would mimic 
opiate withdrawal symptomatology early on in the neonatal course, causing earlier and 
more frequent need for treatment of withdrawal in dually exposed infants. In addition, the 
direct effects of cocaine on neurodevelopment of the fetus could potentially cause an 
anatomic or neurophysiologic basis for a longer-term altered neurologic status in cocaine- 
exposed infants. This altered baseline of functioning could affect the appearance of 
neonatal withdrawal symptoms, such that the neonatal abstinence syndrome is essentially 
changed in these infants. Delineating such questions may serve to improve the treatment 
and understanding of long-term outcome in infants exposed to narcotics and cocaine 




The purpose of the present study was to prospectively examine the following 
hypothesis: Cocaine use among pregnant women maintained on methadone increases the 
duration and the severity of the withdrawal syndrome among their infants. The severity of 
withdrawal was indexed by infant length of stay in the hospital, duration of treatment with 





The study sample consisted of pregnant narcotic-addicted women maintained on 
methadone, and their infants, born at Yale New Haven Hospital (YNHH). Women were 
recruited to participate in the study through a methadone maintenance program for opiate 
addicted individuals offered through the Substance Abuse Treatment Unit of the Yale 
University School of Medicine Department of Psychiatry. Women eligible for the study were 
participants of the methadone program who had delivered a child while on methadone, 
during a period of 23 months (October, 1995 - August, 1997). During this period, 24 infants 
were born at YNHH to methadone-maintained women. 
All of the pregnant women in the study sample received their daily methadone dose 
at the Substance Abuse Treatment Unit. Urine screens for elicit drugs (cocaine, heroin, 
methamphetamine, benzodiazepines, and barbiturates) were performed routinely and 
randomly during the mothers’ methadone maintenance course. Women participated in 
regular group counseling sessions for pregnant substance users as a part of the methadone 
maintenance program, with direct regular contact with a trained substance abuse treatment 
nurse. 
Recruitment to the study was performed through the group counseling sessions, 
with study coordinators obtaining consent from the mothers during their pregnancy to have 
access to the drug treatment records of the mothers, as well as follow the infant in the 
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hospital for narcotic withdrawal. Informed consent for participation in the study was 
obtained by one of the researchers (B.T.). All pregnancy, drug history, and infant 
information was gathered with the maintenance of strict confidentiality, as approved by the 
institutional review committee of the Yale University School of Medicine. 
Study protocol 
During pregnancy, information was gathered on daily methadone dose, urine 
toxicology, pregnancy complications, and medication use. All infants were delivered at Yale 
New Haven Hospital, and mother and infants charts were reviewed for prenatal and delivery 
information at the time of hospitalization. Infants were routinely admitted to the Special 
Care Nursery and observed for withdrawal symptoms within the first 48 hours of life. Each 
infant was transferred to the Children’s Clinical Research Center within 24 hours of 
beginning medication for narcotic withdrawal when it was determined that there were no 
other complications needing intensive care unit observation. Gestational age was 
estimated by attending pediatricians in the newborn nursery using the Ballard criteria.110 
Abstinence scoring 
Drug withdrawal assessment was performed by nursing staff in the CCRC trained to 
use the abstinence scoring system of Finnegan,33 modified (see Figure 2), which measures 
21 signs of withdrawal including increased tone, tremulousness, tachypnea, decreased 
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sleep, and feeding disturbances. Scores were assigned every eight hours, and the initial 
assessment was made in the first eight hours after birth. Nursing staff performing the 
assessments were blinded to the drug history of the mother, with information only that the 
mother had taken methadone during pregnancy. Treatment was routinely begun for 
withdrawal when withdrawal scores exceeded 12 for two consecutive scoring periods. The 
first drug prescribed for withdrawal symptoms was paregoric in all infants. If the infant 
remained symptomatic, phenobarbital was added. In one infant, no medications were used 
to treat narcotic withdrawal specifically. An increase or decrease in dosage of withdrawal 
medication was determined by the infant’s withdrawal symptoms. Infants were always 
weaned off medication before discharge from the hospital and were not transferred to 
another institution or released home until they were symptom free. 
Information regarding the infant’s withdrawal course was recorded on a daily basis, 
focusing on the following parameters: individual shift withdrawal scores; total daily 
withdrawal score; medication type, dose, and frequency of administration; weight gain; 
feeding type and amount; and frequency of perinatal problems such as jaundice, respiratory 
distress, or dysmorphic features. 
Statistical analysis 
We compared groups with a one-way ANOVA test, and Pearson’s chi-square. P< 




Twenty-four women who were receiving methadone during pregnancy through 
SATU, and who delivered infants at YNHH were identified in this study period. One mother 
refused access to her drug history information as a part of the study, and thus data on the 
infant were not included in the present analysis. In the final analysis, data from 23 mother 
and infant sets were used. 
Table 1 shows the demographic characteristics of the sample. Women in this 
sample were usually in their mid-twenties (mean 26.9, S.D. 5.4), and had had multiple 
previous pregnancies (mean 3.7, S.D. 2.0). The sample was predominantly Caucasian 
(56.5%) with 26.1% of Hispanic ethnicity and 17.4% African-American. The HIV status was 
known for 17 women, one of whom was positive. Of the women for whom hepatitis B and C 
test results were available (n = 20), three were positive (13%), with one positive for hepatitis 
B and C, and two for hepatitis C only. Fifteen of the 23 mothers presented to the 
methadone clinic at some point in their pregnancy, and the remaining eight were already in 
the methadone program when they became pregnant. Mothers had been receiving 
methadone for a mean of 26.7 weeks (SD 12.3) at the time of delivery. 
Maternal urine toxicology 
Fourteen mothers (60.9%) who were receiving methadone also reported regular use 
of cocaine or had positive urine screens for cocaine during pregnancy. When mothers who 
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used cocaine during their pregnancy in addition to methadone were compared to mothers 
maintained on methadone who did not use cocaine, there were no differences in maternal 
age, ethnicity, number of pregnancies, or the frequency of tobacco use. There was no 
difference in methadone dose at the time of delivery between the two groups. There 
seemed to be a trend toward later enrollment in the methadone program for mothers who 
also used cocaine during pregnancy, however, the difference did not reach statistical 
significance. The mean gestational age at enrollment for non-cocaine exposed of 8.2 
weeks (SD 8.4) and for cocaine-exposed of 12.0 weeks (SD 11.69), F=.7006, p=.4120. 
Other drug use in pregnancy was similar between the two groups, with no positive urine 
screens for amphetamines, and near equal numbers in each group using benzodiazepines. 
Of those who used cocaine during pregnancy, three (21.4%) also had positive urine screens 
for benzodiazepines. Of the nine mothers who did not use cocaine while maintained on 
methadone, two (22.2%) had positive urine screens for benzodiazepines throughout 
pregnancy. 
Perinatal outcome 
There were seven male and sixteen female infants. As indicated in table 2, the 
mean gestational age for the overall sample was 37.5 weeks by Ballard criteria (S.D. 3.7) 
with a range of 27 to 41 weeks. The mean birth weight for the overall group was 2646 g 
(S.D. 692) and four infants were small for gestational age. The most frequent perinatal 
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complication was low birth weight, with 39.1% of the overall sample born at under 2500 
grams. In addition, 34.8% of the group of 23 infants were delivered at a gestational age of 
less than 37 weeks. One infant was bom at 27 weeks, with a birthweight of 830 grams. 
There was a trend toward the cocaine-using women to have more frequent preterm labor, 
and a greater number of perinatal problems, however the differences were not found to be 
statistically significant. Fourteen infants (60.9%) had additional complications during 
hospitalization. Of these, the most common was hyperbilirubinemia (21.7%), with two 
infants with positive Coombs results. Three infants (13%) had a hospital course that was 
complicated by infection. Similarly, three infants (13%) were observed to have at least one 
episode of apnea while in the hospital. Two infants were diagnosed with a cardiac 
arrhythmia, and one infant was found to have a heart murmur, macrocephaly, and 
dysmorphic features. One infant tested HIV positive during the first month of life. 
The infants withdrawing from methadone spent an average of 34.3 days (S.D. 18.7; 
range 13-85) in the hospital. Infants were treated with medication for withdrawal for an 
average of 27.6 days (S.D. 19.7; range 0-81). The majority of infants showed withdrawal 
symptoms within the first 24 hours (mean 13.2 hours, S.D. 10.8), and were started on 
medication for withdrawal at an average of 43.3 hours of age (S.D. 56.2; range 4-264). 
Paregoric was the first medication used in all infants, and phenobarbital was added to 
paregoric for treatment of continued withdrawal symptoms in three cases. One infant 
required no medication for withdrawal. 
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Withdrawal course by cocaine exposure status 
Several parameters were used to compare the withdrawal course of infants whose 
mothers used cocaine in addition to methadone (n=14) and those who did not (n=9). The 
severity of the withdrawal course was measured by the first and maximum withdrawal 
symptom scores, the maximum dose of paregoric required, the length of stay in the 
hospital, the total number of days on withdrawal medication, and the addition of 
phenobarbital to paregoric for adequate withdrawal treatment. Complications which 
affected the hospital course of the infant, such as prematurity or apnea, were noted and 
compared between the two groups as a measure of poor perinatal outcome. 
When infants exposed to cocaine plus methadone were compared to those whose 
mothers did not use cocaine, the cocaine exposed group trended toward a shorter 
withdrawal course, with trends toward a shorter duration of medication treatment, shorter 
length of stay, and fewer number of days on the highest doses of paregoric. However, the 
statistical differences were not significant to show a strong association between cocaine 
exposure and a shorter withdrawal course. Cocaine-exposed infants required medication 
for withdrawal symptoms at a later age than the methadone-only infants (53.0 versus 28.2 
hours of life), but the difference did not reach statistical significance. Also, cocaine-exposed 
infants tended to require a fewer number of days at the highest doses of paregoric (3.9 
versus 7.9 days), a difference that was not statistically significant. There were no 
differences in first withdrawal scores, age at first withdrawal symptoms, highest dose of 

26 
paregoric required, duration of medication treatment, or length of stay in the hospital 
between the cocaine exposed and cocaine non-exposed groups. 
Three infants required the addition of phenobarbital to paregoric for the treatment of 
more severe withdrawal symptoms. Two infants who received phenobarbital were exposed 
to cocaine, and one was exposed only to methadone. One infant who was not exposed to 
cocaine prenatally required no treatment with paregoric for withdrawal, and one who was 
exposed to cocaine in addition to methadone required only two days of medication 
treatment for withdrawal. The number of infants experiencing complications while in the 
hospital was six (66.7%) for the cocaine-exposed and eight (57.1%) for the group not 
exposed to cocaine, a difference that did not reach statistical significance. Those who were 
born at less than 2500 grams were approximately evenly distributed between groups, with 
four (44.4%) in the group not exposed to cocaine and five (35.7%) in the cocaine-exposed 
group of infants. In addition, one infant was born at under 30 weeks, and was a part of the 
cocaine-exposed cohort. However, there was no difference overall in gestational age 
between the two groups (37.9 weeks and 37.3 weeks). Of the four infants who were 




Effect of maternal methadone dose 
In the present analysis, cocaine exposure was not significantly correlated with 
specific measures for severity of narcotic withdrawal, and only showed trends toward a less 
prolonged course of treatment. However, maternal methadone dose at the time of delivery 
did seem to be a significant contributor to the quality of the infant’s withdrawal course. 
Maternal methadone dose was positively correlated with the number of days that infants 
spent at the highest doses of paregoric [correlation coefficient (r) = .53, p < .01], In 
addition, there was a fair correlation between methadone dose at the time of delivery and 
length of stay of the infant in the hospital (r=.37, p < .08), and the highest dose of paregoric 
required for treatment of withdrawal (r=.23, p <.30). There was a negative correlation at a 
fair level between maternal methadone dose and the age of the infant at the time of first 
withdrawal symptoms (r= -.37, p <.09), and with age at the time of first medication treatment 
(r= -.24, p <.30). The infants (n=3) who required the addition of phenobarbital to paregoric 
for adequate treatment of withdrawal had been exposed to methadone at an average daily 
dose of 90 mg at the time of delivery, whereas the overall group mean daily dose was 77.8 
mg. 
Effect of benzodiazepine exposure 
During the data collection phase of the study, it became evident that a number of 
infants were consistently exposed to benzodiazepines in utero. This drug exposure 
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information was incorporated into a separate analysis to study the effect of benzodiazepine 
exposure on infant withdrawal course. We compared infants who were exposed to 
benzodiazepines in addition to methadone to the infants who were exposed to methadone 
without benzodiazepines. The cocaine exposure status was not used as a factor in this 
portion of the analysis. When mothers who used benzodiazepines were compared to 
mothers who did not use benzodiazepines during pregnancy (Table 4), it was found that 
benzodiazepine users were maintained on a higher dose of methadone and had a 
significantly higher daily dose of methadone at the time of delivery (F=9.92, p = .005). The 
infants of benzodiazepine-using mothers had significantly longer hospital stays (F=8.29, p 
<.01), longer duration of withdrawal medication treatment (F=10.37, p < .01), and spent 
more days at the highest doses of paregoric (F=5.36, p < .05). There were no significant 
differences in first withdrawal score, age at first withdrawal score, age at first medication 
treatment, or the highest dose of paregoric required to treat withdrawal symptoms. The 
number of complications experienced while in the hospital was equal for infants exposed to 
benzodiazepines and those who were not exposed to benzodiazepines (.94 and 1.20 
respectively). The addition of phenobarbital was required for the treatment of withdrawal in 





Relationship of cocaine exposure to severity of withdrawal 
In the present study, the relationship between cocaine exposure and the severity of 
the neonatal abstinence syndrome was investigated in a prospective manner. The primary 
hypothesis of this study was that a combination of methadone and cocaine use during 
pregnancy contributed to a more prolonged and potentially more severe neonatal 
withdrawal course than would be expected with exposure to methadone alone. This 
hypothesis was not proven by the findings in this prospective cohort. On the contrary, there 
is a suggestion that in the group exposed to cocaine in addition to methadone there was a 
trend toward a shorter and less severe withdrawal course. Although not found to be 
statistically significant, the data suggested that infants who were exposed to cocaine had a 
shorter duration of treatment with withdrawal medications, shorter length of stay, and fewer 
number of days on the highest doses of paregoric. These findings suggest that the effect of 
cocaine on withdrawal from methadone in infants is small, and either has no contributory 
effect to the overall severity of narcotic withdrawal, or accounts for only a mild degree of 
shortening in the duration of withdrawal symptoms. 
The results of this study are in contrast, somewhat, to the retrospective view 
performed by Mayes and Carroll,107 looking at a cohort of women who received methadone 
during pregnancy through the same treatment program as women in the present study. 
Data from 68 women and infant pairs were collected, and analyzed for measures of 
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withdrawal severity which parallel the present study. In that cohort, cocaine exposure 
resulted in significantly higher first withdrawal scores, but there were no significant 
differences in the amount of time on withdrawal medication or the maximum required doses 
of paregoric. Those results suggested that the effect of cocaine, if any, on neonatal opiate 
withdrawal was most notable in the initial phase of withdrawal. 
Another study with results conflicting with the present findings was performed by 
Fulroth et al.106 They studied the withdrawal course of 86 infants, 17 of whom had positive 
urine screens for both heroin and cocaine, and 14 for heroin only at the time of birth. They 
found that 21% of the infants exposed only to heroin required withdrawal treatment, 
compared with 47% of infants exposed to both heroin and cocaine. The conclusion drawn 
from this data was that cocaine had a synergistic effect on the withdrawal syndrome seen 
after in utero heroin exposure. 
However, a third study, performed by Ryan et al,108 found that cocaine exposure 
may have lessened or had no effect on the severity of withdrawal in opiate-exposed infants. 
The most significant findings included lower birth weight, length, and head circumferences 
for cocaine-exposed infants when compared with a group of infants not exposed to cocaine 
or methadone. In addition, their data suggested a higher rate of fetal loss and infant 
mortality after cocaine exposure in pregnancy. It was noted that episodes of abstinence 
symptoms occurred less frequently in infants exposed to a combination of cocaine and 
methadone in 19 of the 21 symptom categories on the Finnegan scale. This trend was not 
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found to be statistically significant, and thus the conclusion of the authors was that maternal 
cocaine use had no effect on the severity of neonatal abstinence syptomatology. However, 
it might be suggested, that had a larger population of infants been studied, there may have 
been significance to the trend toward a less severe withdrawal course in the cocaine- 
exposed infants. 
That we did not find a significant effect of cocaine on neonatal narcotic withdrawal is 
most consistent with the results of Ryan et al,108 Mayes and Carroll,107 and studies of opiate 
withdrawal in adults who are also using cocaine.104 However, Fulroth and colleagues106 
found an increased severity of withdrawal in infants exposed to cocaine in addition to 
heroin. Three aspects of the present study may account for these differences. The present 
study prospectively followed women through pregnancy to identify specific drug exposure in 
the newborn, as opposed to relying solely on the results of urine toxicology at the time of 
delivery. Second, all infants were followed prospectively for withdrawal symptoms in a 
study protocol that was pre-defined and monitored specifically for the reduction of bias in 
scoring. Third, all of the women identified as study subjects were enrolled in a methadone 
maintenance program, with monitoring for concomitant health problems and illicit drug use. 
Methadone dose effect on withdrawal severity 
Consistent with previous research,30 45 111 in our study there was a significant 
positive correlation between maternal methadone dose at the time of delivery and the 
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severity of withdrawal as measured by the number of days that infants spent on the highest 
doses of paregoric, and the length of stay of the infant in the hospital. Studies of the 
predictive factors for the severity of neonatal withdrawal from methadone have most often 
found maternal methadone dose to be the most significant predictor of withdrawal 
severity.30'45,111 Doberczak et al46 found that higher initial plasma methadone levels were 
associated with more rapid declines of drug levels in methadone-exposed neonates. The 
more rapid rate of decrease in serum methadone levels after birth correlated significantly 
with acuity of central nervous system withdrawal signs observed in their sample of infants. 
In an earlier study by Ostrea et al,30 neonatal narcotic withdrawal was examined 
prospectively to determine the effect of multiple factors on severity of symptoms. In a large 
cohort of infants, they found that the only significant correlation with severity of withdrawal 
was with the maternal methadone dose. Similarly, in a chart review of 40 women treated 
with methadone during pregnancy, Malpas et al112 found a strong association of higher 
maternal methadone doses with increased length of stay and duration of medication 
treatment for infants experiencing opiate withdrawal symptoms. 
With such clear evidence that maternal methadone dose positively correlates with 
an increased severity of neonatal withdrawal, it has been suggested that women should be 
placed on lower-dose methadone regimens in the later stages of pregnancy,30,45,11V112 or 
that opiate addicts should be detoxified during pregnancy.50 In contrast, in our study 
population, the methadone treatment program tended to increase the daily dose of 
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methadone when there was evidence that a woman was also using cocaine in pregnancy. 
Thus, cocaine use could have been indirectly associated with a more severe narcotic 
withdrawal course. However, it is important to note, there was no difference in the mean 
methadone dose at the time of delivery between cocaine and non-cocaine users in our 
study. 
In the present study, there was a difference in the total number of weeks that 
women received methadone during pregnancy. Although not found to be statistically 
significant, there was a trend toward later enrollment in the methadone program by about 
four weeks for the mothers who also used cocaine during pregnancy. Thus, women who 
used cocaine were more likely to have also used illicit opiates for a longer duration during 
their pregnancy, and may have had lower cumulative exposure to methadone over the 
gestation. Many have suggested that the relationship between methadone dose and 
severity of withdrawal is actually due to an accumulation of methadone in fetal tissues 
which occurs particularly in the last trimester of pregnancy.27 109 Also, there is evidence that 
heroin use during pregnancy produces less severe neonatal withdrawal manifestations than 
methadone maintenance.113'116 Therefore, the tendency for infants to be exposed to less 
cumulative methadone and more heroin in utero may account for the trend toward a less 
severe withdrawal course in our cohort of cocaine-exposed infants. 
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Benzodiazepine exposure effect 
A significant finding from our data was that benzodiazepine (BZD) exposure was 
associated with longer hospital stays, longer duration of withdrawal medication treatment, 
and more days at higher doses of paregoric for the infants. The finding of a more severe 
withdrawal course in these infants was in agreement with published literature on newborn 
outcome after prenatal BZD exposure. BZDs easily cross the placenta and accumulate in 
the fetal adipose tissue.117,118 There is evidence that neonates have a limited capacity to 
metabolize BZDs and may experience symptoms of intoxication or passive addiction after 
prenatal exposure.119 BZD intoxication symptoms have been described as low Apgar 
scores, hypotonia, hypothermia, respiratory and neurologic depression.120 Withdrawal 
symptoms in newborns exposed to diazepam in utero have been described as a high 
pitched cry, increased muscle tone, and increased regurgitation.121 Laegreid et al122 studied 
17 infants of women who had been prescribed benzodiazepines during pregnancy, looking 
at neurologic and behavioral conditions in the neonatal period. Their results were 
significant for diminished reflexes such as the Moro and optical blink reflexes in infants 
exposed to BZD, when compared to a reference group of infants without a history of drug 
exposure. In addition, there were increased findings of drowsiness, tremor, startling, and 
poor sucking in the BZD-exposed group. 
The similarity in clinical appearance of benzodiazepine-exposed and narcotic- 
exposed infants reveals the difficulty of sorting out the impact of poly-drug exposure on 

neonatal outcome. First, testing for benzodiazepines was not routine in the first year of 
enrollment in our study, and maternal reporting of illicit drug use is not consistently reliable.5 
Thus, infants who were exposed to benzodiazepines may have been missed, and a 
misclassification of subjects may have occurred. Second, women who were found to be 
abusing benzodiazepines while on methadone maintenance routinely had the daily doses of 
methadone increased. In this manner, the effect of benzodiazepines on the severity of 
narcotic withdrawal symptoms was intensified. Third, the abuse of benzodiazepines may 
often be associated with an increased severity of illicit opiate abuse or with other drug use 
in pregnancy. Therefore, the question of the specific effects attributable directly to 
benzodiazepines is difficult to isolate. In our study, benzodiazepine exposure seemed to 
correlate with a more severe withdrawal course. However, because there was an even 
distribution of BZD exposure between the cocaine-exposed and non-cocaine-exposed 
groups (21.4% and 22.2% respectively) there presumably was equal effect of BZD 
exposure on the withdrawal symptom scoring in each group in our study. 
Pregnancy complications 
Although the overall group of poly-drug exposed pregnancies in our study does 
appear to be at higher risk for complications than non-drug exposed pregnancies, cocaine 
exposure as a single factor was not associated with an increased risk of poor perinatal 
outcome in our sample. Our findings are in contrast to the results of others who have 
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studied cocaine use in pregnancy.108,123'125 Most often, cocaine use in pregnancy has been 
reported to be associated with prematurity, low birth weight, and decreased head 
circumference.124,125 Chasnoff et al123 studied 52 cocaine-using women and compared them 
to 73 women who were maintained on methadone during pregnancy. The women in the 
two separate groups were similar in type of prenatal care, socioeconomic status, and 
cigarette, marijuana, and alcohol use. The cocaine-using women in the study had 
significantly higher rates of premature labor, abruptio placentae, fetal monitor abnormality, 
and fetal meconium staining than women in the methadone group. However, there was no 
effect of cocaine use on neonatal gestational age, birth weight, length, and head 
circumference compared to methadone use. 
The Chasnoff et al123 study group was most similar to our own, in that pregnancies 
complicated by cocaine use were directly compared to those with in which the mothers used 
methadone. Our cocaine-exposed sample similarly revealed a trend toward a higher rate of 
preterm labor, and increased fetal distress. Notable due to the reported lessened severity 
of withdrawal in preterm infants,109 there was no increased risk of prematurity in the 
cocaine-exposed group in this study. In addition, we did not find a significant difference 
between groups in gestational age, birth weight, or head circumference. This apparently 
low incidence of perinatal morbidity attributable to cocaine exposure is consistent with the 
results of a meta-analysis evaluation published by Lutiger et al.126 In their review of 20 
papers dealing with the effects of cocaine use during pregnancy on pregnancy outcome, the 
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analysis revealed very few adverse effects to be significantly associated with cocaine use 
when compared to control groups of polydrug users. Thus, our results contribute to the 
suggestion that a variety of adverse reproductive effects commonly quoted to be associated 
with maternal use of cocaine may be caused by confounding factors clustering in cocaine 
users. 
Study limitations 
Failure to find a significant effect of cocaine on neonatal withdrawal may reflect 
several limitations of the present sample. First, the assignment of infants to cocaine and 
non-cocaine exposed groups was based on obtaining positive urine screens for cocaine 
during pregnancy in women enrolled in the methadone maintenance program. Although 
urine screens were performed routinely and randomly, mothers presenting for methadone 
treatment later in their pregnancy would be less likely to have had repeated urine screens. 
Therefore, subjects may have been misclassified as non-cocaine using. 
Another problem with the present study was the small number of subjects, and thus 
the inability to show significant differences between groups due to high standard deviations. 
Recruitment into the study could have been broadened to include mothers treated at 
methadone maintenance clinics or delivering at hospitals separate from the YNHH system. 
However, logistical matters precluded the ease with which drug use information may be 
shared between institutions. The enrollment of subjects is actively being continued, such 
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that the sample size of mother and infant pairs may increase, and data may be reanalyzed 
at another endpoint in the near future. 
Thirdly, information on alcohol use during pregnancy was limited for our sample of 
mothers. Maternal reporting of substance abuse in pregnancy is consistently unreliable and 
may underidentify users.5 In addition, there was no objective measure, such as blood 
alcohol levels, used to detect alcohol consumption in methadone-maintained pregnant 
women. This becomes important in interpreting results for any study of poly-drug exposed 
infants. In particular, alcohol exposure during pregnancy has been reported to effect 
newborn autonomic regulation as evidenced by increased tremors and startles,127 and by 
decreased habituation response to novel stimuli such as light or sound.128 In more recent 
studies, specific effects on newborn behavior attributable to alcohol exposure have not been 
detected.84129 However the interactions of cocaine, alcohol, and opiates in newborns are 
not well understood. This makes it difficult to conclude the amount of effect attributable to 
cocaine exclusively in our study when there is little information on concomitant alcohol 
exposure. 
A final methodologic issue was the potential for bias to be introduced, particularly in 
withdrawal scoring and the length of treatment of infants in the hospital. We used the 
abstinence scoring system devised by Finnegan33 to quantitate the presence and degree of 
withdrawal. All scorers were trained in using the scale and were known to be able to score 
infants accurately. However, the items scored on the Finnegan scale allow for some 
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subjective input by the scorer, such as the degree of tremors being judged as mild to 
severe. Such subjectivity in scoring may easily be influenced by observer bias. For 
instance, the nursing staff at YNHH may have had an idea of whether or not each infant 
was exposed to other drugs in utero in addition to methadone. This information is often 
gained through other channels than the infant’s chart or actual urine assay results, and so 
may or may not be accurate. To investigate this potential bias, we gathered information on 
whether scorers believed certain infants were exposed to cocaine prenatally, then 
compared that opinion with actual urine results from the pregnancies. A brief questionnaire 
was given to each nurse who had cared for a given infant during hospitalization, asking 
whether they knew of cocaine exposure in the infant. Data from the nursing staff who cared 
for 11 of the study infants were gathered and analyzed for accuracy of the predictions. In 
the overall sample, respondents were unsure of the exposure history 32.9% of the time. 
However, when nursing staff expressed an opinion that an infant was exposed to cocaine, 
they were correct 78.0% of the time. Therefore, although blinded to the results of maternal 
urine analyses, withdrawal scorers often had an idea of whether the infants had been 
exposed to cocaine in utero, and surely held beliefs about how such exposure affected 
neonatal behavior. Similarly, perceived knowledge of maternal drug use often influences 
when an infant will be discharged from the hospital, and potentially the length of treatment 
for withdrawal. Thus, length of stay and duration of treatment as endpoints to a study may 
be inherently laden with bias. 
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In conclusion, exposure to cocaine in addition to opiates during pregnancy may not 
have an effect on the severity of the neonatal abstinence syndrome, as measured by length 
of treatment, dosage of withdrawal medications, length of stay, and first withdrawal scores. 
Further investigations that attempt to time more accurately the infant’s last exposure to 
cocaine, as well as to define more clearly the level of alcohol and benzodiazepine exposure 
will be useful in more precisely defining whether or not cocaine exposure further 
complicates the withdrawal of the opiate exposed infant. A commonly expressed view 
among women in methadone maintenance programs is that cocaine use will minimize their 
infants’ withdrawal from methadone. That belief is not supported by the present study, and 
based on the literature on cocaine exposure in pregnancy many mothers may be placing 
their infants at increased risk of perinatal morbidity or mortality by adhering to this belief. 
Thus, there is a strong clinical need for further education and monitoring in the methadone- 




Signs and Symptoms Associated with Neonatal Abstinence 
Central Nervous System: Gastrointestinal: 
Irritability Poor Feeding 
High-pitched cry Regurgitation 
Exaggerated Moro Reflex Loose Stools 
Tremors Excessive Sucking 
Increased Muscle Tone Uncoordinated Sucking 
Increased Deep Tendon Reflexes 
Increased Rooting Reflex Respiratory: 
Seizures Respiratory Distress 
Frequent Yawning 







Modified Finnegan Abstinence Scoring Form 
CENTRAL NERVOUS SYSTEM DISTURBANCES: 
Irritability: 
which Interferes with ability to sleep at least 
2 hours after feeding 
which interferes with ability to bottle feed 
(requiring gavage) 
inconsolable while being held 
Mild tremors undisturbed 
Moderate-severe tremors undisturbed 
Mild tremors disturbed 
Moderate-severe tremors disturbed 




Fever < 101 (37.2-38.2) 



































Demographic Characteristics of Study Sample 
n = 23 
Mean S.D. Ranae 
Maternal Age 26.9 5.4 17-38 
Number of Pregnancies 3.7 2.0 1-8 
Methadone Dose (mg/day) 77.8 22.5 35-120 
Weeks on Methadone at Delivery 26.7 12.4 2.5-41 




Maternal HIV Status 
Positive 1 (4.3) 
Negative 16(69.6) 
Unknown 6(26.1) 
Maternal Hepatitis Status 






Infant Study Subjects: Perinatal Data 
Cocaine Negative Cocaine Positive 
N=9 N=14 
Mean (S.D.1 
Gestational Age (wk) 37.9(3.1) 
Birthweight (gm) 2677 (620) 
Head Circumference (cm) 32.2 (2.6) 
Weight at Discharge (gm) 3396(1029) 
Complications: N (%) 
Delivery @ <37 weeks 3 (33.3) 
Fetal distress @ delivery 0 
Meconium stained fluid 1 (11.1) 
Less than 2500 gms 4 (44.4) 
Small for Gestational Age 3 (33.3) 
Hyperbilirubinemia 3 (33.3) 
Infections 0 
HIV positive 1 (11.1) 
Apnea 1 (11.1) 
Other 6(26.1) 
Total number complications 22 
Mean (S.D.’l 
37.3 (4.2) F (1,21) = .03 
2627 (757) F (1,21) = .12 
31.9(2.7) F (1,20) = .05 





















Mean (S.D.) Mean fS.D.) 
Length of Stay (d) 36.6 (25.2) 32.9(14.1) F (1,21) = .21 
Duration of Therapy (d) 30.4 (26.9) 25.8(14.1) F (1,21) = .30 
First Withdrawal Score 10.3(6.7) 10.5(4.6) F (1,21) = .005 
Age at First Withdrawal (hr) 12.7(10.0) 13.6(11.7) F (1,21) = .03 
Age at First Medication (hr) 28.2 (23.6) 53.0 (68.8) F (1,21) = 1.07 
Highest Dose Paregoric (drops/24hr) 74.9 (37.5) 82.0 (33.6) F (1,21) = .22 
# Days at Highest Dose 7.9(11.8) 3.9 (2.1) F (1,21) = 1.54 











Mean (S.D.I Mean fS.D.) 
Methadone Dose at delivery (mg) 71.4(19.5) 101.0(14.3) F (1,21) = 9.92** 
Length of Stay (d) 29.2(13.5) 52.8 (24.7) F (1,21) = 8.29** 
Duration of Therapy (d) 21.8(13.7) 48.6 (25.0) F (1,21) = 10.37** 
First Withdrawal Score 9.8 (5.6) 12.8(4.1) F (1,21) = 1.25 
Age at First Withdrawal Score (hr) 15.0(11.4) 7.0 (5.5) F (1,21) = 2.24 
Age at First Medication (hr) 46.6 (62.2) 31.4 (26.0) F (1,21) = .28 
Highest Dose Paregoric (drops/24hr) 73.6 (35.1) 99.6 (25.3) F (1,21) = 2.36 
# Days at Highest Paregoric Dose 3.7 (3.2) 11.8(14.4) F (1,21) = 5.36* 
Phenobarbital Added, N(%) 1 (5.6%) 2 (40%) X!= 4.09* 
* p < .05 
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